NAUSICALM TABLET 50MG [SIN15193P]
Active ingredients: CYCLIZINE HYDROCHLORIDE
Last updated on 9 October 2026
Product Info
NAUSICALM TABLET 50MG
[SIN15193P]
Product information
Active Ingredient and Strength | CYCLIZINE HYDROCHLORIDE - 50 MG |
Dosage Form | TABLET |
Manufacturer and Country | SIGMA LABORATORIES LTD. - INDIA |
Registration Number | SIN15193P |
Licence Holder | APEX PHARMA MARKETING PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R06AE03 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
Indications
Nausicalm is indicated for the prevention and treatment of nausea and vomiting associated with motion sickness and radiotherapy.
Dosing
Dosage and Administration
For the Treatment of nausea induced by radiotherapy:
Adults and children over 12 Years: One tablet every 6 to 8 hours, as required with a little water (up to a maximum of 3 tablets in 24 hours)
Use in the Elderly: There have been no specific studies of cyclizine in the elderly. Experience has indicated that normal adult dosage is appropriate.
For the Prevention of Travel Sickness:
Adults and children over 12 Years: One tablet every 6 to 8 hours (up to a maximum of 3 tablets in 24 hours), as required with a little water, first taken 1–2 hours before departure.
The score line only serves to facilitate breaking for ease of swallowing and does not divide the tablet into equal half-doses.
This product should not be used for more than 48 hours at a time
Contraindications
Contraindications
Nausicalm should not be given to individuals with known hypersensitivity to cyclizine or in individuals with severe heart failure.